A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Status:
Completed
Trial end date:
2014-10-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate safety and efficacy of abiraterone in
participants with metastatic castration-resistant prostate cancer (mCRPC) and who have not
received prior chemotherapy (treatment of disease, usually cancer, by chemical agents).